Antiangiogenic therapy in lung cancer: Focus on vascular endothelial growth factor pathway

Grzegorz Korpanty, Elizabeth Smyth, Laura A. Sullivan, Rolf A. Brekken, Desmond N. Carney

Research output: Contribution to journalShort survey

37 Scopus citations

Abstract

Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.

Original languageEnglish (US)
Pages (from-to)3-9
Number of pages7
JournalExperimental Biology and Medicine
Volume235
Issue number1
DOIs
StatePublished - Jan 2010

Keywords

  • Angiogenesis
  • Antiangiogenesis
  • Lung cancer
  • VEGF

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Antiangiogenic therapy in lung cancer: Focus on vascular endothelial growth factor pathway'. Together they form a unique fingerprint.

  • Cite this